Should You Buy Canopy Growth Stock on the Rebound?

Canopy Growth showed strong Q1 fiscal 2027 results with 13% revenue growth across all business divisions, improved gross margins, and significantly reduced losses. However, the company remains a penny stock with over 400% share dilution in three years. While the business turnaround is promising, the article recommends most investors monitor rather than buy, citing the sector's history of underperformance and the need to see sustained improvement before investing.

09/05/2026, 7:15 AM • The Motley Fool

Is Aurora Cannabis Stock a Buy as Curaleaf Pushes a Hostile Takeover Bid?

Curaleaf has launched a hostile takeover bid for Aurora Cannabis at $4 per share, which Aurora's board has rejected. While Aurora has transformed into a leaner, profitable medical cannabis company with strong international operations and a solid balance sheet, investors shouldn't buy the stock purely as a takeover bet. The company's genuine turnaround in medical cannabis and European expansion could make Curaleaf's offer undervalued, but there's no guarantee the deal will close or be increased.

08/28/2026, 6:15 AM • The Motley Fool

The Cannabis M&A Wave Is Here. Curaleaf Proved It. Here's Whether Green Thumb Should Ride It -- or Wait to Be Swept Up.

Curaleaf initiated a takeover bid for Aurora Cannabis, signaling an M&A wave in the cannabis sector following expected federal rescheduling from Schedule I to Schedule III. Green Thumb Industries, a profitable multi-state operator, has the financial capacity to pursue acquisitions but is likely to favor disciplined, smaller bolt-on deals in limited-license states over aggressive megamergers, prioritizing share buybacks and organic growth.

08/23/2026, 6:30 PM • The Motley Fool

Curaleaf's Hostile Takeover Bid for Aurora Is Just the Tip of the Iceberg for Cannabis Consolidation. These 2 Stocks Could Be the Biggest Winners.

The cannabis sector is undergoing consolidation as weaker players exit and stronger companies acquire competitors. Curaleaf has made an unsolicited $4 per share bid for Aurora Cannabis. The article identifies Canopy Growth and Tilray Brands as the biggest potential winners in this consolidation trend, with Canopy benefiting from its balance sheet reset and Tilray diversifying beyond marijuana into alcohol and consumer brands.

08/21/2026, 8:15 AM • The Motley Fool

Is Curaleaf Stock a Buy With Its Attempted Hostile Takeover of Aurora Cannabis Under Way?

Curaleaf formally launched a hostile takeover bid for Aurora Cannabis on August 18, 2026, offering $4 per share (45% premium) with potential to reach $5 per share. The analyst recommends passing on Curaleaf stock, citing regulatory mismatches between U.S. and Canadian markets, complicated international distribution networks, and neither company's proven profitability track record. Aurora shares trade at a discount to the offer price, suggesting investor skepticism about deal completion.

08/20/2026, 7:30 AM • The Motley Fool

Curaleaf Wants to Buy Aurora Cannabis for $272 Million. Is Canopy Growth the Next Marijuana Takeover Target?

Curaleaf launched an unsolicited $272 million bid to acquire Aurora Cannabis at $4 per share, signaling renewed consolidation in the cannabis industry. The move raises questions about whether Canopy Growth could become the next acquisition target. While Canopy has valuable global medical cannabis assets and established brands, its complex corporate structure and ongoing turnaround make it a less obvious fit for potential acquirers.

08/16/2026, 12:30 AM • The Motley Fool

Curaleaf Just Announced a Hostile Takeover Bid for Aurora Cannabis. Here’s What This Means for Investors.

Curaleaf launched a hostile takeover bid for Aurora Cannabis at $4 per share (45% premium), comprising 0.34 Curaleaf shares plus $0.75 cash, with a $5 per share cap. Aurora's board will consider the offer but criticized the financing details and price cap. The combination appeals due to Aurora's strong medical marijuana business with higher margins, though hostile bids have historically struggled.

08/12/2026, 1:19 AM • The Motley Fool

Canopy Growth Is Restating Two Years of Financials Before June 15 Earnings -- Here's What CGC Investors Need to Know Right Now

Canopy Growth announced it will restate financial results for two years due to a technical accounting error involving share-settled warrants that should have been classified as liabilities rather than equity. The company states the restatement won't impact revenue, operating income, cash flows, or key performance metrics. However, the stock remains a risky penny stock in a struggling marijuana sector facing intense competition and illicit market pressures. Most investors should avoid the stock until it achieves sustainable profitability and the restatement is complete.

05/22/2026, 11:15 PM • The Motley Fool

Is Aurora Cannabis Stock Ready to 10X in the Next Pot Boom?

Aurora Cannabis has lost 96% of its value since 2021 and faces significant challenges despite recent U.S. cannabis reclassification from Schedule I to Schedule III. The company has no meaningful U.S. market presence after shutting down its Reliva CBD operations in 2023, and with weak revenue growth and consistent losses, it is unlikely to capitalize on potential industry growth. The stock is viewed as a wealth destroyer rather than a 10x opportunity.

02/26/2026, 6:14 AM • The Motley Fool

Recreational Cannabis Market Report 2026-2035: A $3.32 Billion Market by 2030 - AI-Enabled Product Innovation, Novel Cannabis Beverages and Experience-Based Offerings Reshape Premiumization

The recreational cannabis market is projected to grow from $2.24 billion in 2025 to $3.32 billion by 2030, with a CAGR of 7.8-8.2%. Growth is driven by increasing legalization, public acceptance, demand for high-THC products, and innovation in premium edibles, beverages, and vape formats. Key players are launching innovative products and pursuing strategic acquisitions to capitalize on expanding market opportunities.

02/20/2026, 5:59 AM • GlobeNewswire

Trump's Cannabis Rescheduling Order Could Finally Kill A Crushing Tax Rule And Transform US Weed Stocks, Says Expert

President Trump's executive order to reschedule cannabis to Schedule 3 could eliminate Section 280E of the Internal Revenue Code, allowing U.S. cannabis operators to deduct business expenses for the first time. This represents the most significant federal cannabis policy shift in over 50 years. However, challenges remain including inability to list on major exchanges and lack of banking safe harbor provisions.

01/19/2026, 8:16 AM • Benzinga

Do These 2 Cannabis Stocks Have a Future?

President Trump's executive order rescheduling cannabis from Schedule 1 to Schedule 3 has improved the regulatory landscape for the cannabis industry, offering easier banking access and business expense deductions. However, analyst Prosper Junior Bakiny argues that Canopy Growth and Aurora Cannabis lack attractive investment prospects despite this development, citing ongoing federal illegality, interstate commerce restrictions, and poor financial performance in their home market.

12/28/2025, 11:09 PM • The Motley Fool

High Hopes: Pot Stocks Blaze As Trump Eyes Rescheduling

President Trump is considering rescheduling marijuana from Schedule I to Schedule III, which could potentially remove tax burdens on cannabis businesses and improve their financial prospects.

12/17/2025, 11:26 AM • Benzinga

Canopy Growth To Acquire MTL Cannabis

Canopy Growth will acquire MTL Cannabis for approximately 125 million Canadian dollars in a cash-and-stock transaction, expanding its medical cannabis market presence in Canada and improving national distribution capabilities.

12/15/2025, 11:36 AM • Benzinga

Why Aurora Cannabis Stock Just Rocketed Higher

President Trump is considering rescheduling marijuana from Schedule I to Schedule III, which could make cannabis business operations easier and potentially boost marijuana companies like Aurora Cannabis.

12/12/2025, 12:12 PM • The Motley Fool